{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:45:41Z","timestamp":1784119541909,"version":"3.55.0"},"reference-count":21,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Res"],"published-print":{"date-parts":[[2015]]},"abstract":"<b><i>Purpose:<\/i><\/b> To study the structural, visual and refractive outcomes of intravitreal injection of aflibercept monotherapy in patients with high-risk prethreshold type 1 retinopathy of prematurity (ROP). <b><i>Design:<\/i><\/b> Prospective nonrandomized interventional case series study. <b><i>Patients and Methods:<\/i><\/b> 1 mg\/0.025 ml intravitreal aflibercept was administered for patients with high-risk prethreshold type 1 ROP. The primary outcomes studied were unfavorable structural outcome, unfavorable visual outcome and unfavorable refractive outcome. The secondary outcomes were absence of recurrence, ocular and systemic adverse events. <b><i>Results:<\/i><\/b> Twenty-six eyes were enrolled in the study; all had completed 1 year of follow-up. The mean birth weight was 991 \u00b1 266 g (range: 875-1,105 g); the mean gestational age at birth was 26.33 \u00b1 2.1 weeks (range: 24-30 weeks); 9 eyes were graded as ROP with stage 2+, zone I retinopathy, 14 eyes had stage 3+ disease in zone II and 3 eyes were diagnosed with stage 3 disease in zone I. Twenty-five eyes (96.2%) showed a favorable structural and 21 (80.1%) a favorable visual outcome, and the median refractive error after 1 year was 0.75 dpt (range: -9.5 to +4). <b><i>Conclusions:<\/i><\/b> Intravitreal injection of aflibercept monotherapy is an easy, safe and effective alternative modality of therapy for high-risk prethreshold type 1 ROP. A further multicenter study with a longer duration of follow-up is required. \u00a9 2014 S. Karger AG, Basel<\/jats:p>","DOI":"10.1159\/000364809","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T07:42:21Z","timestamp":1417419741000},"page":"15-20","source":"Crossref","is-referenced-by-count":63,"title":["Structural, Visual and Refractive Outcomes of Intravitreal Aflibercept Injection in High-Risk Prethreshold Type 1 Retinopathy of Prematurity"],"prefix":"10.1159","volume":"53","author":[{"given":"Abdelrahman G.","family":"Salman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aza M.","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2014,11,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(91)32074-8"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1988.01060130517027"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.3.311"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1994.01090140028007"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318169faee"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.12.1684"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-008-0865-9"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318296e26d"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.01.014"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302276"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000166"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-011-9249-6"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.09.026"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.172398299"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0B013E31822C290F"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318217373c"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00695-9"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.72"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2004.045815"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31815075b0"}],"container-title":["Ophthalmic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/364809","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/364809","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/364809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:52:02Z","timestamp":1745430722000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000364809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,29]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,1,1]]},"published-print":{"date-parts":[[2015,1,26]]}},"URL":"https:\/\/doi.org\/10.1159\/000364809","archive":["Portico"],"relation":{},"ISSN":["0030-3747","1423-0259"],"issn-type":[{"value":"0030-3747","type":"print"},{"value":"1423-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,29]]}}}